DMRA (Damora Therapeutics) YoY EBITDA Growth: 54.29% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMRA Damora Therapeutics Inc DMRA
28 GF Score
Price $29.94
! 3 Warning Signs
View Full Analysis

What is Damora Therapeutics YoY EBITDA Growth?

Damora Therapeutics DMRA +1.10% 28 YoY EBITDA Growth is 54.29% as of Mar. 2026. GuruFocus rates DMRA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Damora Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 54.29%.

Damora Therapeutics's EBITDA per Share for the three months ended in Mar. 2026 was $-0.90.

Damora Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Damora Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Damora Therapeutics YoY EBITDA Growth Chart

Damora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 71.95 -16.55 43.92 45.56 -747.79

Damora Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.31 38.26 28.17 -2,421.30 54.29
DMRA
28GF Score
Damora Therapeutics Inc DMRA
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Damora Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Damora Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-154.687--18.246)/ | -18.246 |
=-747.79 %

Damora Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.896--1.96)/ | -1.96 |
=54.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 54.29% mean?
Damora Therapeutics (DMRA) has a YoY EBITDA Growth of 54.29% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Damora Therapeutics and its competitors.
Is Damora Therapeutics' YoY EBITDA Growth too high?
Damora Therapeutics' current YoY EBITDA Growth is 54.29%. Overall, Damora Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Damora Therapeutics' YoY EBITDA Growth compare to SLBT and BCAX?
Damora Therapeutics' YoY EBITDA Growth of 54.29% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Damora Therapeutics and its competitors. Damora Therapeutics's current YoY EBITDA Growth is 54.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damora Therapeutics stock overvalued right now?
Damora Therapeutics (DMRA) has a current YoY EBITDA Growth of 54.29%. The current YoY EBITDA Growth is 54.29%. Damora Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Damora Therapeutics (DMRA), the current YoY EBITDA Growth is 54.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Damora Therapeutics Business Description

Address 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02109
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
28GF Score

Get the complete analysis for DMRA

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.94
Price